文献速递前列腺癌

转移性去势抵抗性前列腺癌间歇与连续多西他赛治疗的III期PRINCE研究

Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE).
PubMed 文献 · BJU Int · 2018-05-06

PRINCE研究为研究者发起的随机III期试验,纳入187例化疗初治mCRPC患者,比较间歇与连续多西他赛(每周35 mg/m2或3周75 mg/m2)的1年生存非劣效性(margin δ=0.125)。结果显示间歇组达到1年生存非劣效标准(95%CI -0.12, 18, P=0.022),但事后分析OS未达非劣效,PFS与TTF无显著差异,安全性相当。

要点

  • 间歇多西他赛在1年生存上非劣于连续治疗,但OS非劣效未获证实。
  • 间歇组中位治疗假期110天,占总体治疗时长38%。
  • 两组PFS、TTF及安全性无显著差异,但研究未达计划样本量。

核心结论

  • 间歇多西他赛化疗在1年生存上非劣于连续治疗,但OS的非劣效性未达到。

研究设计与样本

  • 研究者发起的随机III期研究,纳入187例化疗初治mCRPC患者,随机分配至间歇或连续多西他赛组。
  • 多西他赛给药方案为每周35 mg/m2或3周75 mg/m2。
  • 主要终点为1年生存,非劣效界值δ=0.125。

主要发现

  • 156例可评估患者中每组78例,间歇组达到1年生存非劣效标准(双侧95%CI -0.12, 18, P=0.022)。
  • 事后分析显示OS未达非劣效。
  • PFS和TTF组间差异无统计学意义。
  • 间歇组中位治疗假期110天(范围13-486天),占总体治疗时长的38%。
  • 两组安全性特征相当。

关键数值与推荐

  • 1年生存非劣效界值δ=0.125。
  • 间歇组1年生存非劣效检验P=0.022(双侧95%CI -0.12, 18)。
  • 间歇组中位治疗假期110天(13-486天),占总体治疗时长38%。

临床怎么用

  • 间歇多西他赛可作为mCRPC化疗的选项之一,但需注意OS非劣效未证实,应个体化评估。
  • 治疗假期中位110天可能减少累积毒性并改善生活质量,但需密切监测。

局限性

  • 研究未能招募到计划样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate non-inferiority of intermittent docetaxel compared to continuous docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENT AND METHODS: The investigator initiated randomised phase III study included 187 chemotherapy-naïve patients with mCRPC who were allocated to two treatment arms: intermittent docetaxel and continuous docetaxel. Docetaxel was applied in both arms as weekly (35 mg/m2 ) or 3-weekly (75 mg/m2 ). The primary endpoint was 1-year survival, which was tested for non-inferiority (margin δ = 0.125). The secondary endpoints were: overall survival (OS), progression-free survival (PFS), median time to treatment failure (TTF), and toxicity. RESULTS: Of 156 eligible patients, 78 were allocated to each arm. The intermittent treatment met the non-inferiority criteria for 1-year survival (two-sided 95% confidence interval, -0.12, 18, P = 0.022), but not for OS, according to the result of a post hoc analysis. The differences between the study arms in PFS and TTF were not significant. The median (range) treatment holiday in the intermittent arm was 110 (13-486) days, or 38% of the overall treatment duration. Safety profiles of both study arms were comparable. The main limitation of this study was that the planned number of patients could not be recruited. CONCLUSION: Intermittent docetaxel chemotherapy was non-inferior to continuous therapy for 1-year survival; non-inferiority in regard to OS was not reached.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cash H, Steiner U, Heidenreich A, et al. Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE). BJU Int. 2018. PMID: 29633515. doi:10.1111/bju.14239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。